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Zusammenfassung
Die Sterblichkeitsrate bei Brustkrebs konnte vor allem
dank der Früherkennung und systemischer Therapie-
maßnahmen seit den 1990er Jahren signifikant gesenkt
werden. Alle drei Therapiesäulen, bestehend aus zytosta-
tischer Therapie, endokriner Therapie und zielgerichteter
Antikörpertherapie, sind derzeit notwendige Instrumente
zur kurativen Therapie des primären Mammakarzinoms.
Dieser Artikel fasst die Evidenzbasis für den Einsatz ver-
schiedener Chemotherapieschemata bei Patientinnen
mit einem primären, nodalpositiven Mammakarzinom,
auch in Zusammenhang mit einer zielgerichteten HER2/
neu-Therapie, zusammen.
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Summary
Breast cancer-associated mortality has been significantly
reduced since the 1990s, mainly because of early diagno-
sis and systemic therapeutic interventions. All three ther-
apy components – cytostatic therapy, endocrine therapy
and targeted antibody therapy – are at present necessary
tools for the curative treatment of primary breast cancer.
This article reviews the evidence base for the use of vari-
ous chemotherapy schedules in patients with primary,
node-positive breast cancer, including schedules in com-
bination with targeted HER2/neu therapy.
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Introduction
The understanding of breast cancer as a primarily local dis-
ease has undergone a fundamental change in the last few
decades. While throughout most of the previous century
breast cancer was still mainly conceived of as a predominantly
local disease [1, 2], the radical nature of surgery can now be re-
duced to a minimum by the use of breast-conserving proce-
dures [3–5] and axillary sentinel lymph node excision [6]. The
systemic use of cytostatic and endocrine therapeutic modali-
ties has simultaneously provided a major overall survival ben-
efit for patients treated in accordance with current therapeutic
standards [7–11].
The therapy recommendations for the use of conventional and
dose-dense chemotherapy and trastuzumab have not essen-
tially changed following the St. Gallen Consensus Conference
2007, and are basically in conformity with the S3 guidelines of
the German Cancer Society and the German guidelines of the
AGO Organkommission Mamma (Working Group for Gyne-
cological Oncology in the Breast Organ Committee), which
can be downloaded in detail from http://www.ago-online.org.
Chemotherapy: Anthracycline Therapy versus Taxane
Therapy
Up to a few years ago, adjuvant standard chemotherapy com-
prised threefold anthracycline combinations (≥ 30 mg epiru-
bicin/week) for 6 cycles, which was shown to be superior to
first-generation chemotherapy regimens (e.g. cyclophospha -
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mide/methotrexate/fluorouracil (CMF) or doxorubicin (adri-
amycin)/cyclophosphamide (AC)) [11]. However, the results
of a good half dozen randomized studies on the use of taxanes
in adjuvant therapy of node-positive breast cancer suggest al-
most without exception that the use of taxanes can improve
survival by another 3–6% compared to pure anthracycline
therapy (fig. 1). Considered altogether, these data justify the
AGO guidelines proposing taxane-containing schedules as a
therapeutic option for the adjuvant treatment of node-posi-
tive patients. The heterogeneity of the available research find-
ings pertaining to the role of taxanes in the adjuvant therapy
of breast cancer, however, still leaves many aspects unre-
solved. Besides the question as to which patients benefit most
from the use of taxanes, the scheduling of the group of sub-
stances is still the subject of scientific debate. Sequential tax-
ane therapy appears to have become more established in re-
cent years. The Taxit 216 study of A. Bianco was presented at
the American Society of Clinical Oncology (ASCO) 2006
meeting (Abstract no. 520); in this study 972 patients were
treated either with 4 cycles of epirubicin 120 mg/m2 q3w fol-
lowed by 4 cycles of CMF (E-CMF), or with the same sched-
ule plus 4 cycles of docetaxel 100 mg/m2 q3w (E-T-CMF). The
interim analysis was performed after a median follow-up of 53
months. The addition of taxane was observed to lead to a re-
duction in the risk of relapse of 21% (p = 0.05) and in the mor-
tality risk of 28% (not significant). In the BIG 2–98 study pre-
sented by J. Crown, sequential taxane therapy with A-T-CMF
also provided a significant improvement in relapse-free sur-
vival compared to A-CMF (p = 0.035, LBA no. 519), while a
combination with AT-CMF did not. At the San Antonio
Breast Cancer Symposium (SABCS) 2006, however, the data
of the MA-21 study performed to compare FEC120, 4×AC-
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Fig. 1. Overview of prospective randomized
studies comparing adjuvant anthracycline-
based and taxane-based chemotherapies in
breast cancer.
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Fig. 2. Kaplan-Meier analysis of relapse-free
survival in the MA-21 study [20]
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4×paclitaxel and a dose-dense anthracycline taxane schedule
were greeted with great surprise. While the dose-dense sched-
ule and FEC120 were equally effective, the conventional AC-
paclitaxel arm proved inferior both to the FEC120 (p = 0.005)
and the dose-dense schedule (p = 0.0006) (fig. 2).
Two of the main presentations at the SABCS 2007 were de-
voted to assessing the value of taxanes as adjuvant therapy. In
the TACT Trial, 4162 patients were randomized between an-
thracycline-based chemotherapy (8×FE60C or E-CMF) and
taxane-based chemotherapy (4×FE60C, followed by 4×doc-
etaxel100). Astonishingly, the use of taxane was not found to
provide demonstrable benefit either in terms of relapse-free
survival (hazard ratio (HR) 0.67, p = 0.62) or overall survival
(HR = 0.98, p = 0.76).
In another study by Jones et al. (US Oncology 9735), adjuvant
chemotherapy with 4 cycles of AC was compared with 4 doc-
etaxel 75-cyclophosphamide (fig. 3). While the results of the
overall study were already published in 2006 in the Journal of
Clinical Oncology [12], the results presented in San Antonio
focused on patients aged 65 years or more. As in the overall
study, the elderly patients also showed both a significant re-
lapse-free (p = 0.033) and an overall survival benefit (p =
0.032) (fig. 4). However, these results should be interpreted
with caution as 4 cycles of AC cannot be regarded as current
state of the art. Further studies on anthracycline-free regimens
in comparison to modern standard treatment are warranted.
Also at SABCS 2007, Sir Richard Peto presented interesting
calculation models for the effectiveness of modern taxane-
containing chemotherapy. Since modern taxane therapies have
only been tested against anthracycline-containing schedules in
the adjuvant situation, a direct assessment of the absolute sur-
vival benefit provided by this form of chemotherapy has so far
not been possible. By statistically combining the individual
therapeutic benefits of different chemotherapy schedules,
Peto [22] was able to calculate an HR of 0.46 (2p = 0.00001) in
the < 50-year age group, i.e. a reduction in the probability of
mortality by 54% due to taxane-containing chemotherapy
(table 1).
At the annual ASCO conference 2008, two further studies
were presented which complete the overall picture for the
comparison between anthracycline-containing schedules with
or without taxanes. In the Spanish GEICAM study, 6 cycles of
TAC (75/50/500 mg/m2) were compared with 6 cycles of FAC
(500/50/500 mg/m2) in patients with node-negative breast can-
cer. This study confirmed a significant benefit in terms of re-
lapse-free survival (p = 0.02), but not of overall survival. In
the German WSG/AGO study, on the other hand, Prof. Dr. U.
Nitz was able to demonstrate both a relapse-free (HR 1.77,
95% confidence interval (CI): 1.28–2.46) and an incipient
overall survival benefit in patients with 1–3 axillary lymph
node metastases. Guidelines will now have to define whether
taxane-based regimens should not only be used in node-posi-
tive but also in node-negative breast cancer (www.ago-on-
line.org).
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Fig. 3. US Oncology study 9735: Study flow chart comparing anthracy-
cline-based versus taxane-based chemotherapy [12].
Fig. 4. US Oncology study 9735: Survival data SABCS 2007 comparing
anthracycline-based versus taxane-based chemotherapy [21].
Table 1. EBCTCG data for approximation of chemotherapy benefit in
patients under 50 years with primary breast cancer [22]
Treatment HR HR
recurrence breast cancer 
years 0–4 mortality
CMF vs. no CT 0.56 (0.05) 0.68 (0.05)
Anthracyclines vs. CMF 0.84 (0.05) 0.81 (0.05)
Taxanes vs. anthracyclines 0.84 (0.04) 0.86 (0.05)
Taxanes vs. no CT 0.38 (0.07) 0.46 (0.08)
(multiplication of 3 RRs) 2p < 0.00001 2p < 0.00001
RR = Relative risk.
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Is the Use of Anthracyclines Necessary in Patients with
HER2/neu-Negative Breast Cancer?
The debate surrounding the need to use anthracyclines in pa-
tients with HER2/neu-negative breast cancer was again con-
ducted vigorously at ASCO 2008. The opening meeting of
ASCO 2008 devoted to breast cancer addressed the question
whether anthracycline-based chemotherapy still constitutes a
modern therapeutic approach to HER2/neu-negative breast
cancer. At the meeting chaired by Prof. Eric Winer of the
Dana-Farber Cancer Institute, this subject was considered
from clinical, tumor biological and molecular biological per-
spectives. Prof. K. Gelmon discussed the survival benefits pro-
vided by anthracyclines based on a review of previous anthra-
cycline studies. However, she also reported on the meta-analy-
sis recently published by Gennari et al. in the Journal of the
National Cancer Institute (JNCI) which demonstrates that an-
thracyclines show no superiority in HER2/neu-negative tu-
mors (fig. 5) [13].
Prof. A. di Leo from Florence emphasized that no topoiso-
merase IIα overexpression is usually detectable in HER2/neu-
negative breast cancer and that the target for anthracyclines is
therefore absent. The US Oncology 9735 study, which com-
pared 4 cycles of AC with 4 docetaxel 75-cyclophosphamide,
was also discussed again. Prof. E. Winer then summarized the
undesirable effects of the anthracyclines with reference to sev-
eral review articles. A risk of long-term myocardial insuffi-
ciency of about 2% is generally to be expected, but is higher in
elderly patients. Studies to re-assess the value of the anthracy-
clines are currently being planned both in the USA and in
Germany.
Conventional Dosage versus Dose-Dense 
Chemotherapy or High-Dose Chemotherapy?
The results of two randomized studies suggest that increasing
the dose density, i.e. shortening the time intervals between the
cycles, has a positive effect on therapeutic efficacy. An Ameri-
can Intergroup Study and the German ETC study showed that
dose-dense treatment resulted in a significant reduction in the
risk of relapse [14, 15]. At ASCO 2004, the first survival analy-
sis of the German AGO ETC study was presented by V.
Möbus (fig. 6) [16]. This study tested a modified Henderson
schedule (4 cycles of EC 90/600 followed by 4 cycles of pacli-
taxel 175) versus the dose-dense and dose-intensified ETC
schedule (3 cycles of epirubicin 150 followed by 3 cycles of pa-
clitaxel 225 and 3 cycles of cyclophosphamide 2500). The data
of 1284 patients confirmed the expected high myelotoxicity of
the ETC schedule, with a Grade 4 leukopenia rate of 46% de-
spite prophylactic administration of granulocyte colony-stimu-
lating factor (G-CSF). The rate of febrile neutropenia, howev-
er, was within a tolerable range at 7%. Without primary pro-
phylactic administration of epoietin-α 28% of the patients,
and with epoietin still 12% of the patients, required transfu-
sions because of the ETC chemotherapy. After a 28-month
follow-up, a statistically significant advantage was seen in
favor of the ETC schedule, both in terms of relapse-free sur-
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Fig. 5. Meta-analysis
of anthracycline effi-
cacy in relation to
HER2/neu status [13].
244_250_06008_janni:244_250_06008_janni  22.08.2008  14:06 Uhr  Seite 247
vival (p = 0.0009) and overall survival (p = 0.039). At SABCS
2006, the research group was then able to present the second
interim analysis. After a median follow-up of 5.2 years, the sig-
nificant relapse-free survival benefit in favor of the ETC ther-
apy arm was confirmed with an HR of 0.72 (p = 0.0008). Simi-
lar results were produced by the comparison of overall sur-
vival (HR 0.76, p = 0.029) [16]. This database was used to de-
sign the German GAIN study, which is at present actively
recruiting.
At SABCS 2005, an update of the American Intergroup Trials
INT C9741 was presented which, although still showing a
highly significant relapse-free survival benefit for chemothera-
py in the 2-week versus the 3-week interval (p = 0.012), also
showed a significant but unexpectedly limited overall survival
benefit (p = 0.049). Overall, the results suggest that increasing
the dose density provides a potential benefit by increasing the
dosage in the era of anthracycline and taxane therapy without,
however, establishing a new therapy standard at the present
time because of the associated toxicity.
At the St. Gallen Consensus Conference 2007 there was no
majority in favor of recommending dose-dense therapy, al-
though the convincing data of the German ETC study men-
tioned above were not discussed. For patients with HER2/neu
overexpression in the tumor, dose-dense administration of
E/AC-T (32.4%) or FEC-D (36.1%) still received the highest
approval rates. A similar pattern was seen for negative HER2/
neu status: dose-dense administration of E/AC-T (36.4%) or
FEC-D (25.0%).
In a meta-analysis of the effectiveness of adjuvant high-dose
therapy presented by Berry et al. at the SABCS 2007, the data
of 6210 patients from 15 studies were evaluated. Although a
disease-free survival benefit with an HR of 0.85 (95% CI
0.81–0.94; p = 0.0001) could be significantly improved by the
use of high-dose chemotherapy in the total population, overall
survival (p = 0.16) was uninfluenced (fig. 7). Furthermore, in
the subgroup analysis, no population could be defined that
had benefited more from the use of high-dose chemotherapy.
A recommendation for high-dose chemotherapy with stem
cell support was already unanimously rejected at the St.
Gallen Consensus Conference 2007.
Antibody Therapy: Soon Herceptin for All?
Targeted humoral therapy with the antibody trastuzumab is
probably the most cost intensive but for certain patients also
the most effective innovation in the systemic therapy of breast
cancer in association with chemotherapy.
The benefits of the adjuvant use of trastuzumab and the car-
diotoxicity known to be associated with its use in metastatic
breast cancer must be evaluated critically against this back-
ground. At ASCO 2005, data on the use of trastuzumab in the
primary management of early breast cancer were presented
for the first time. A combined analysis of the two American
studies NSABP B31 and NCCTG N9831 evaluated therapy
with AC followed by paclitaxel, with or without extension of
therapy with trastuzumab over 1 year. The use of trastuzumab
resulted in a highly impressive, subgroup-independent im-
provement in relapse-free survival in HER2/neu-positive pa-
tients (immunohistochemistry (IHC) +++ or fluorescent in
situ hybridization (FISH) +) of 67–85% after 4 years and, after
a median follow-up of only 2 years, in an incipiently significant
improvement in overall survival (p = 0.015) [17].
In the global HERA study with 4482 patients presented by M.
Piccart, a highly significant, absolute benefit in relapse-free
survival of 12% after the use of trastuzumab for 1 year was
observed after a median follow-up of only 1 year (HR 0.54,
95% CI 0.43–0.67) [18]. This benefit was also seen in all sub-
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Fig. 6. Study design of the German ETC study on the efficacy of dose-
dense/dose-intensive chemotherapy in breast cancer [16].
Fig. 7. Survival curves for adjuvant use of high-dose chemotherapy in a
meta-analysis [23].
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groups, although no overall survival benefit could (yet) be
demonstrated. In an update of the HERA study presented by
I. Smith at ASCO 2006, the results of ASCO 2005 were not
only reproduced, but for the first time a significant overall sur-
vival benefit was also demonstrated. The risk of cancer-associ-
ated mortality was reduced by 34% (3-year overall survival
92.4% versus 89.7%, HR 0.66, p = 0.012).
The BCIRG 006 study for the first time evaluated the efficacy
of trastuzumab in association with anthracycline-free chemo-
therapy. In this three-armed study, 3222 patients with primary
breast cancer were randomized between an adjuvant therapy
with 4 cycles of AC followed by 4 cycles of docetaxel with
(AC-TH) or without trastuzumab (AC-T), or a combination of
docetaxel with carboplatin and trastuzumab (TCH) (fig. 8).
After a median follow-up of 36 months, at the SABCS 2006 D.
Slamon presented the second interim analysis of the BCIRG
006 which within a three-arm design is evaluating the efficacy
of AC-T versus AC-TH versus TCH in primary, HER2/neu-
positive breast cancer. The trastuzumab-containing arms AC-
TH and TCH showed practically identical efficacy both in
terms of relapse-free (77 versus 83% versus 82%) and overall
survival (86 versus 92 versus 91%) with a significant advan-
tage compared to trastuzumab-free therapy. This benefit was
present independent of nodal status, hormone receptor status
and tumor size. In the anthracycline-free arm, however, there
were fewer Grade 3/4 toxicities such as neutropenia, gastroin-
testinal toxicities and neuropathies. Since higher efficacy of
anthracyclines associated with coamplification of topoiso-
merase IIα, still assumed in the previous year, was not con-
firmed, TCH represents a new option in the adjuvant therapy
of node-positive breast cancer in the presence of HER2/neu
overexpression.
As anticipated, the panel of experts at the St. Gallen Consen-
sus Conference 2007 followed this convincing evidence and
voted 91.9% in favor of a 1-year trial of trastuzumab in pa-
tients with chemotherapy and a HER2/neu-overexpressing
tumor. A 9-week course of therapy following the FinHer study
was approved by only 14.3% of the panelists. 92.1% of the ex-
perts considered a positive (+++) immunohistochemical
demonstration of HER2/neu overexpression sufficient, while
FISH testing (FISH for all?) was rejected by 84.2% [19]. The
German AGO guidelines clearly recommend trastuzumab
treatment for 1 year in HER2/neu-positive patients undergo-
ing chemotherapy.
Summarizing, patients, and only those with a clearly HER2/
neu-overexpressing tumor and an indication for adjuvant
chemotherapy, should receive adjuvant therapy with trastu-
zumab, at present for 12 months. Patients with a significant
history of cardiac illness who fulfill the criteria for chemother-
apy and trastuzumab therapy should consider anthracycline-
free cytostatic therapy with a combination of a taxane, a plat-
inum derivative and trastuzumab.
Conclusions
Chemotherapy with anthracycline/taxane is regarded as the
standard treatment for node-positive women. In these cases,
either a combination (e.g. TAC with docetaxel) or a sequential
therapy schedule (e.g. EC/AC-T with paclitaxel or FEC-DOC
with docetaxel) can be used. High dose frequency regimens
such as EC-T with 2-week therapy (with paclitaxel) and dose-
intensified ETC (with paclitaxel) are, in the hands of experi-
enced physicians, an evidence-based option in node-positive
patients, especially with greater nodal involvement. These
schedules are not yet approved and should therefore be used
primarily in trials or, in specially justified individual cases, re-
served for ‘off-label-use’.
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Fig. 8. Study design of the BCIRG 006 study
comparing anthracycline-containing and anthra-
cycline-free chemotherapy in combination with
trastuzumab therapy [24].
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Adjuvant 1-year trastuzumab therapy following primary sys-
temic or adjuvant chemotherapy is standard in HER2/neu-
positive breast cancer (HER2 3+ or FISH+). It is approved re-
gardless of age, nodal status or time elapsed since primary
surgery. Indication should be assessed independent of nodal
250 Breast Care 2008;3:244–250 Janni/Rack/Harbeck/Bauerfeind/Sommer/
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status or patient age, provided there is no contraindication to
the planned therapy. According to the present state of knowl-
edge, therapy can be started together with taxane chemother-
apy or implemented completely after chemotherapy.
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